Table 1 Participant demographics, clinical characteristics, and metabolic measures.

From: Effects of neuroactive metabolites of the tryptophan pathway on working memory and cortical thickness in schizophrenia

 

Schizophrenia (n = 195)

Healthy controls (n = 70)

Test statistic

p-Value

Male/female

110/85

37/33

χ2 = 0.26

0.61

Smoker/non-smoker

52/143

17/53

χ2 = 0.15

0.70

Age (years)

35.60 (13.03)

39.74 (11.82)

t = 2.33

0.02

Education (years)

12.37 (3.21)

12.91 (2.56)

t = 1.28

0.20

BMI

23.43 (4.36)

23.92 (3.07)

t = 1.02

0.31

CPZ

266.31 (349.77)

NA

NA

NA

PANSS total score

72.36 (17.13)

NA

NA

NA

Working memorya

45.16 (11.43)

57.78 (7.65)

F = 78.19

<0.001

Processing speeda

44.96 (8.73)

57.09 (8.51)

F = 92.99

<0.001

Attention/vigilancea

43.64 (9.85)

56.81 (9.08)

F = 59.66

<0.001

Verbal learninga

46.98 (12.17)

57.41 (8.34)

F = 39.31

<0.001

Visual learninga

45.23 (10.56)

53.39 (8.47)

F = 37.73

<0.001

Reasoning and problem solvinga

45.70 (10.70)

55.88 (7.81)

F = 69.88

<0.001

Social cognitiona

46.20 (10.97)

53.22 (9.95)

F = 24.76

<0.001

MCCB composite scorea

43.91 (10.21)

57.83 (7.93)

F = 103.64

<0.001

5-HI (ng/ml)a

8.57, 8.44 (2.79)

7.85, 7.73 (2.12)

F = 2.54

0.11

KYNA (ng/ml)a

6.42, 5.77 (3.36)

8.59, 8.14 (3.09)

F = 34.38

<0.001

QUIN (ng/ml)a

49.62, 44.71 (24.73)

54.18, 50.51 (16.55)

F = 5.63

0.02

5-HI/KYNAa

1.69, 1.36 (1.30)

1.01, 0.94 (0.40)

F = 33.61

<0.001

QUIN/KYNAa

8.67, 8.04 (3.8)

6.77, 6.36 (2.44)

F = 18.05

<0.001

  1. Data reported as [mean (SD)], except for 5-HI, KYNA, QUIN, 5-HI/KYNA, and KYNA/QUIN as [mean, median (SD)].
  2. CPZ chlorpromazine equivalent, DBP diastolic blood pressure, 5-HI 5-hydroxyindole, KYNA kynurenic acid, MCCB MATRICS Consensus Cognitive Battery, NA not applicable, PANSS Positive and Negative Syndrome Scale, QUIN quinolinic acid, SBP systolic blood pressure.
  3. aStatistics included sex and age as covariates.